ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Celgene buys into Prothena programs

by Lisa M. Jarvis
March 26, 2018 | APPEARED IN VOLUME 96, ISSUE 13

 

Celgene will pay Prothena $100 million up front as part of a pact to develop antibodies against three neuroscience drug targets: tau, a protein linked to Alzheimer’s disease; TDP-43, a protein implicated in amyotrophic lateral sclerosis; and an undisclosed target. The deal, which also calls for Celgene to take an equity stake in Prothena worth $50 million, comes at a time when Celgene is trying to bolster its neurodegenerative disease pipeline. Celgene can license the U.S. rights to drug candidates after Phase I studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment